Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + sotorasib
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of afatinib, a pan-ErbB tyrosine kinase inhibitor, and sotorasib (LUMAKRAS), a KRAS G12C inhibitor. This combination targets both KRAS G12C mutations and the ErbB family of receptors, potentially overcoming resistance mechanisms to KRAS inhibition alone. The combination has shown antitumor activity in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), including those who previously progressed on sotorasib monotherapy.
- Brand names
- LUMAKRAS (for sotorasib)Giotrif (for afatinib)
- Other names
- sotorasib and afatinib
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on afatinib + sotorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + sotorasib.